<DOC>
	<DOCNO>NCT00636792</DOCNO>
	<brief_summary>This phase 2 , single-arm , open label , multicenter study evaluate efficacy safety combination VELCADE , bendamustine , rituximab subject relapse refractory follicular lymphoma , receive 4 dos rituximab . Subjects may sensitive refractory prior therapy , include rituximab .</brief_summary>
	<brief_title>A Phase II Study VELCADE ( Bortezomib ) Combination With Bendamustine Rituximab Subjects With Relapsed Refractory Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Male female subject 18 year age old Pathological diagnosis follicular lymphoma ( grade ) Documented relapse progression follow prior antineoplastic therapy Have receive 4 prior dos rituximab At least 1 measurable tumor mass ( &gt; 1.5 cm long axis &gt; 1.0 cm short axis previously irradiate , grow since previous irradiation No clinically significant central nervous system lymphoma Karnofsky performance status ( KPS ) ≥50 ( equivalent Eastern Cooperative Group Oncology Group [ ECOG ] status ≤2 Diagnosed treated malignancy nonHodgkin 's lymphoma ( NHL ) within 2 year first dose , previously diagnose malignancy NHL radiographic biochemical marker evidence malignancy . Subjects prostate cancer treat definitive radiotherapy serum prostatespecific antigen ( PSA ) &lt; 1 ng/mL exclude . Subjects also exclude basal cell squamous cell carcinoma skin completely resect , situ malignancy adequately treat . Prior treatment VELCADE® bendamustine Antineoplastic ( include unconjugated therapeutic antibody toxin immunoconjugates ) , experimental , radiation therapy within 3 week Day 1 Cycle 1 Nitrosoureas within 6 week Day 1 Cycle 1 Radioimmunoconjugates within 10 week Day 1 Cycle 1 Autologous stem cell transplant within 3 month Day 1 Cycle 1 , prior allogeneic stem cell transplant time Major surgery within 2 week Day 1 Cycle 1 Platelet transfusion within 7 day Day 1 Cycle 1 ( applies subject enrol dose escalation phase . This apply subject enrol phase 2 study ) . Ongoing therapy corticosteroid . Prednisone ≤15 mg per day equivalent allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>